Revelation Biosciences (REVB) Expected to Announce Earnings on Friday

Revelation Biosciences (NASDAQ:REVB) is anticipated to post its results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($1.34) per share for the quarter.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.43). On average, analysts expect Revelation Biosciences to post $-49 EPS for the current fiscal year and $-34 EPS for the next fiscal year.

Revelation Biosciences Stock Down 3.9%

NASDAQ REVB opened at $1.00 on Wednesday. The company has a 50-day moving average price of $1.53 and a 200-day moving average price of $3.18. Revelation Biosciences has a 52 week low of $0.96 and a 52 week high of $60.48. The firm has a market capitalization of $15.40 million, a P/E ratio of -0.03 and a beta of -0.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Revelation Biosciences in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.